Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus chemotherapy and brain radiotherapy in first-line ES-SCLC with brain metastases
ChiCTR2600116872Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab in small cell lung cancer (SCLC) and brain metastases, sponsored by Henan Cancer Hospital. Primary endpoint: Progression-Free Survival (PFS). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR2600116872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116872.